Fred Hutch Cancer Center is spearheading a $15 million national clinical trial initiative, funded by the Patient-Centered Outcomes Research Institute, to evaluate whether stem cell transplantation or non-transplant therapies offer superior survival and quality-of-life outcomes for older adults in remission from acute myeloid leukemia.
Acute myeloid leukemia, commonly known as AML, is an aggressive, fast-moving blood cancer that presents complex clinical dilemmas for older patients. Following initial remission, physicians and patients frequently face a difficult fork in the road: whether to pursue a stem cell transplant or continue with non-transplant therapies. For decades, this decision has relied on observational data rather than definitive, large-scale randomized trials.
Led by principal investigator Dr. Mohamed Sorror, a professor in Fred Hutch Cancer Center’s Clinical Research Division and an associate professor of medicine at the University of Washington School of Medicine, the new five-year funding award will support an 18-center U.S. consortium. The initiative will enroll approximately 800 patients to directly compare these treatment pathways across three distinct clinical subgroups.
In Plain English: The Clinical Takeaway
- Stem Cell Transplantation: A procedure replacing diseased bone marrow with healthy stem cells, offering durable long-term disease control but carrying substantial short-term toxicity risks.
- Measurable Residual Disease (MRD): Small numbers of cancer cells that remain in the body after treatment, which often dictate whether a patient needs aggressive follow-up therapy.
- Patient-Centered Endpoints: Trial metrics that evaluate not just overall survival, but physical function, cognitive health, frailty, and daily quality of life.
Addressing Persistent Clinical Uncertainty in Older Populations
According to findings released by the Patient-Centered Outcomes Research Institute, roughly one-third to one-half of older adults with AML lack a clear consensus treatment strategy following remission. While younger or exceptionally robust patients often proceed immediately to transplantation, older adults face unique physiological vulnerabilities. These include co-existing medical conditions, functional decline, and variable disease biology.
“For decades, patients, families and physicians have had to make these life-changing decisions without sufficiently strong comparative evidence,” Dr. Mohamed Sorror explained regarding the initiative. Transplants can secure long-term remission, but the physical tolls are heavy. Conversely, modern non-transplant therapies may preserve day-to-day functional independence for patients who cannot tolerate aggressive conditioning regimens.
The 18-center consortium is designed to bridge this evidence gap by randomizing patients across three carefully defined clinical cohorts. The first group comprises patients with favorable combined health and disease profiles where the survival benefit of a transplant must be weighed against its toxicity. The second group includes patients in first remission with persistent measurable residual disease and intermediate health vulnerability. The third group covers high-risk patients with increased frailty or significant comorbidities.
Comparative Treatment Strategies and Quality-of-Life Metrics
The Fred Hutch-led initiative integrates patient-reported outcomes directly into its core protocol. Caregivers, clinicians, and patients themselves helped shape the study design to ensure it measures factors that matter most to daily existence.
Below is an overview of the trial parameters supported by the Patient-Centered Outcomes Research Institute funding:
| Parameter | Details |
|---|---|
| Funding Agency | Patient-Centered Outcomes Research Institute (PCORI) |
| Award Amount | $15 million over five years |
| Target Enrollment | Approximately 800 patients |
| Participating Centers | 18 medical centers across the United States |
| Primary Investigator | Dr. Mohamed Sorror (Fred Hutch / University of Washington) |
By establishing a multicenter network, researchers aim to capture diverse demographic data and robust statistical power.
Contraindications & When to Consult a Doctor
Individuals interested in clinical trial participation should ask their care team whether they meet the eligibility criteria for the newly launched multicenter consortium.
Advancing Evidence-Based Oncology Care
The launch of this $15 million national initiative marks a significant step forward in closing a long-standing knowledge gap in geriatric oncology. By pairing survival metrics with rigorous evaluations of functional independence, the trial promises to deliver actionable guidance for clinicians worldwide. As patient enrollment begins across the participating U.S. centers, the findings will likely shape clinical guidelines and empower older adults to make informed choices aligned with their personal health goals.
References
- Patient-Centered Outcomes Research Institute (PCORI). Funding Announcement: Comparative Clinical Effectiveness Research in Acute Myeloid Leukemia.
- Fred Hutch Cancer Center. News Release: Fred Hutch Cancer Center to lead $15 million national clinical trial initiative for older adults with acute myeloid leukemia. August 2026.
Disclaimer: This report is provided for informational and educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified health provider with any questions regarding a medical condition.
